Observed — originator lab
Telomerase / telomere length in cultured human cells
Addition of Epithalon to telomerase-negative human fetal fibroblast culture induced catalytic-subunit expression, telomerase enzymatic activity, and telomere elongation (Khavinson, Bondarev, Butyugov, 2003, PMID 12937682). A follow-up from the same group reported that aging human fetal pulmonary fibroblasts lost proliferative potential at passage 34; Epithalon elongated telomeres toward early-passage length and the treated cells made 10 extra divisions (44 passages) versus control (Khavinson et al., 2004, PMID 15455129). These are cell-culture findings from one laboratory. They are not a human lifespan result.
Observed — independent 2025
Telomere / hTERT / ALT in cell lines
Al-Dulaimi, Thomas, Matta, and Roberts (Brunel) treated breast-cancer lines 21NT and BT474 plus normal epithelial and fibroblast cells. qPCR and immunofluorescence showed dose-dependent telomere-length extension in normal cells through hTERT and telomerase upregulation. In the cancer lines, telomere extension also occurred through ALT (alternative lengthening of telomeres); ALT increase was minor in normal cells (PMID 40908429; PMC12411320). This is still in vitro. The paper has a published erratum (PMID 41240216); findings used here are from the opened 2025 abstract, not from numbers that appear only in the unopened PDF.
Observed — ex vivo
PHA-stimulated human lymphocytes
In blood lymphocytes from young (18–22 y, n=5) and middle-aged (49–54 y, n=6) men, AEDG changed relative telomere length in 7 of 11 individuals (increase in 5, decrease in 2). The authors described a “tendency to normalization” versus the group mean. Mitotic index was largely unchanged (Khavinson et al., 2019, PMID 31761987). This is ex-vivo culture of donated blood, not an in-vivo human telomere trial.
Observed — cell culture
Chromatin in cultured lymphocytes
In cultured lymphocytes from persons aged 76–80 years, Epitalon induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes described as repressed by age-related euchromatin condensation (Khavinson et al., 2003, PMID 14647006). Cell culture, not an organismal aging trial.
Opened papers disagree
Melatonin — conflicting results
Khavinson et al. (2012) reported that epithalone stimulated AANAT and pCREB synthesis and increased melatonin in rat pinealocyte culture (PMID 22816096). Djeridane, Khavinson, Anisimov, and Touitou (2003), using a perifusion device on pineal glands from young (9-week) and old (27-month) male Wistar rats, found that Ala-Glu-Asp-Gly had no significant effect on melatonin secretion and did not modify isoproterenol-stimulated melatonin. The authors concluded the tetrapeptide “does not seem to play a role, at least in vitro, in the control of melatonin secretion by the rat pineal gland” (PMID 12809170). Do not state “restores melatonin” as a settled fact. Report both results.
Observed — cell + docking
Neurogenic markers + histone model
In human gingival mesenchymal stem cells, AEDG increased Nestin, GAP43, β-tubulin III, and doublecortin protein and raised those mRNAs 1.6–1.8-fold. Molecular modelling suggested preferred binding to histones H1/6 and H1/3 at DNA-interacting sites (Khavinson et al., 2020, PMID 32019204; PMC7037223). That binding model is computational plus marker expression, not a solved co-structure of AEDG on chromatin in a living human.
Observed — independent
Mouse oocyte aging
Yue et al. (2022) added Epitalon to cultured post-ovulatory mouse oocytes and reported lower ROS, fewer spindle and cortical-granule defects at 12–24 h, higher mitochondrial membrane potential and mtDNA copy number, and less apoptosis by 24 h (PMID 35413689; PMC9037278). In-vitro oocyte aging, not human fertility.
Observed — cell monolayer
High-glucose ARPE-19 wound model
Gatta et al. (2025) reported that AEDG restored impaired scratch-wound closure in high-glucose-injured human retinal pigment epithelial cells and reduced hyperglycemia-associated EMT/fibrosis markers (PMID 40493162; PMC12356729). Cell monolayer, not a diabetic-retinopathy trial.
Proposed / class-level
Compiled actions; mechanism uncertain
Araj 2025 lists antioxidant, neuroprotective, antimutagenic, melatonin, IL-2, thymocyte, AChE/BuChE, and telomerase effects and states it remains uncertain whether these are the sole mechanisms (PMID 40141333). Khavinson 2017 attributes the biological effects of the pineal polypeptide complex to its AEDG component (PMID 29124531). That is the authors’ interpretation of an identification study.
Class study — not Epitalon-only
THP-1 / macrophage inflammation
Epitalon was one of five Khavinson peptides tested together as a class; all five inhibited LPS-stimulated TNF and IL-6 on differentiated THP-1 cells (Avolio et al., 2022, PMID 35408963; PMC8999041). Not an Epitalon-only binding study.
Not shown in a paper opened here
Gaps that matter
No defined cell-surface receptor, Ki table, or crystal structure for AEDG. No proof that marketplace vials reproduce St. Petersburg lot pharmacology. No human in-vivo telomere lengthening after a research-vial protocol. No human lifespan extension, delayed human aging, or a registered randomized longevity trial. No consistent, independently replicated melatonin mechanism (opened papers disagree in vitro). No oral human bioavailability or a research-vial PK curve. ClinicalTrials.gov v2 API search for epitalon OR epithalon OR epithalone OR AEDG returned an empty studies array.
Al-Dulaimi 2025 confirmed telomere-length increase in cells and also reported ALT activation in two breast-cancer lines (21NT, BT474). Do not treat cell-culture telomere elongation as a human telomere or lifespan result. Fly lifespan is not a human result.
